About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker REGN · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 13, 2026A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well…
NCT06097364 · Follicular Lymphoma (FL)
Odronextamab, Rituximab
REGN
Regeneron Pharmaceuticals
Phase 3Active, not recruiting733Jul 29, 2029Registry ↗
Nov 12, 2026Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD)
NCT07933328 · Alcohol-Associated Liver Disease, ALD
ALN-CIDEB, Placebo
REGN
Regeneron Pharmaceuticals
Phase 2Not yet recruiting120May 7, 2029Registry ↗
Nov 12, 2026A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children an…
NCT07559513 · Fibrodysplasia Ossificans Progressiva, FOP
garetosmab
REGN
Regeneron Pharmaceuticals
Phase 3Not yet recruiting18Jul 8, 2030Registry ↗
Nov 12, 2026A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children,…
NCT07220772 · Monogenic Obesity
Mibavademab
REGN
Regeneron Pharmaceuticals
Phase 3Recruiting4Jun 18, 2027Registry ↗
Nov 12, 2026A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe a…
NCT06299098 · Obesity
Trevogrumab-Part A, Trevogrumab-Part B and Part C
REGN
Regeneron Pharmaceuticals
Phase 2Completed
was active, not recruiting
1,005Jun 16, 2026Registry ↗
Nov 12, 2026A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituxi…
NCT06149286 · Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractor…
Odronextamab, Lenalidomide
REGN
Regeneron Pharmaceuticals
Phase 3Recruiting580Apr 30, 2031Registry ↗
Nov 12, 2026A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Ritux…
NCT06091254 · Follicular Lymphoma (FL)
Odronextamab, Rituximab
REGN
Regeneron Pharmaceuticals
Phase 3Recruiting822Feb 29, 2028Registry ↗
Nov 12, 2026A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metaboli…
NCT05519475 · Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
ALN-HSD, Placebo
REGN
Regeneron Pharmaceuticals
Phase 2Active, not recruiting
was recruiting
120Apr 27, 2028Registry ↗
Nov 12, 2026Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Sm…
NCT03088540 · Carcinoma,Non-Small-Cell Lung, Lung Carcinomas, Non-Small-C…
Pemetrexed, Paclitaxel
REGN
Regeneron Pharmaceuticals
Phase 3Completed712Apr 18, 2025Registry ↗
Nov 10, 2026Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis…
NCT07830329 · Hidradenitis Suppurativa
Olatorepatide, Placebo
REGN
Regeneron Pharmaceuticals
Phase 2Recruiting
was not yet recruiting
300Nov 24, 2028Registry ↗
Nov 10, 2026Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Ora…
NCT07430956 · Atrial Fibrillation (AF)
REGN7508, REGN9933
REGN
Regeneron Pharmaceuticals
Phase 3Recruiting2,628Mar 28, 2029Registry ↗
Nov 10, 2026A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Me…
NCT06848088 · Melanoma
Fianlimab+cemiplimab
REGN
Regeneron Pharmaceuticals
Phase 2Active, not recruiting
was enrolling by invitation
28Oct 9, 2030Registry ↗
Nov 10, 2026A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for…
NCT05608291 · Melanoma
Fianlimab, Cemiplimab
REGN
Regeneron Pharmaceuticals
Phase 3Active, not recruiting1,564Jan 15, 2027Registry ↗
Nov 9, 2026Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatiti…
NCT07631637 · Metabolic Dysfunction-Associated Steatohepatitis, MASH
ALN-CIDEB, Placebo
REGN
Regeneron Pharmaceuticals
Phase 2Recruiting360Jan 29, 2029Registry ↗
Nov 9, 2026A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Pr…
NCT05568459 · Hemophilia B
Non-Interventional
REGN
Regeneron Pharmaceuticals
—Active, not recruiting11Nov 20, 2026Registry ↗
Nov 6, 2026Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
NCT07685808 · Overweight or Obesity
Olatorepatide, Placebo
REGN
Regeneron Pharmaceuticals
Phase 2Recruiting360Jan 21, 2028Registry ↗
Nov 6, 2026First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With…
NCT07527923 · Healthy Volunteer, Atopic Dermatitis
REGN20423, Placebo
REGN
Regeneron Pharmaceuticals
Phase 1Recruiting160Aug 14, 2028Registry ↗
Nov 6, 2026REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adu…
NCT07015905 · Venous Thromboembolism (VTE)
REGN7508, Apixaban
REGN
Regeneron Pharmaceuticals
Phase 3Recruiting2,000Feb 20, 2027Registry ↗
Nov 6, 2026Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovari…
NCT06787612 · Ovarian Cancer, Fallopian Tube Cancer
Ubamatamab, Bevacizumab
REGN
Regeneron Pharmaceuticals
Phase 2Recruiting397Jun 30, 2028Registry ↗
Nov 6, 2026A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advance…
NCT06246916 · Melanoma
fianlimab, cemiplimab
REGN
Regeneron Pharmaceuticals
Phase 3Recruiting560Mar 22, 2027Registry ↗
Nov 6, 2026A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it…
NCT05828511 · Multiple Myeloma
Linvoseltamab
REGN
Regeneron Pharmaceuticals
Phase 1/2Active, not recruiting
was recruiting
148Nov 2, 2035Registry ↗
Nov 6, 2026A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomi…
NCT05730036 · Relapsed Refractory Multiple Myeloma (RRMM)
Linvoseltamab, Elotuzumab
REGN
Regeneron Pharmaceuticals
Phase 3Recruiting410Apr 19, 2033Registry ↗
Nov 6, 2026A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in…
NCT05133531 · Paroxysmal Nocturnal Hemoglobinuria
Ravulizumab, Pozelimab
REGN
Regeneron Pharmaceuticals
Phase 3Completed
was active, not recruiting
202Sep 28, 2026Registry ↗
Nov 5, 2026Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease…
NCT07854782 · Metabolic Dysfunction-Associated Steatotic Liver Disease, M…
ALN-CIDEB, Placebo
REGN
Regeneron Pharmaceuticals
Phase 3Recruiting
was not yet recruiting
1,500Mar 3, 2029Registry ↗
Nov 5, 2026A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric…
NCT07675811 · Allergic Conjunctivitis
REGN-2Cat, Freneslerbart
REGN
Regeneron Pharmaceuticals
Phase 3Recruiting570May 31, 2029Registry ↗
Nov 5, 2026Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
NCT07626411 · Atrial Fibrillation (AF)
REGN7508, Apixaban
REGN
Regeneron Pharmaceuticals
Phase 3Recruiting15,364Sep 11, 2029Registry ↗
Nov 5, 2026Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid…
NCT07493304 · Venous Thromboembolism (VTE)
REGN7508, Apixaban
REGN
Regeneron Pharmaceuticals
Phase 3Recruiting1,600Jul 18, 2031Registry ↗
Nov 5, 2026A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants…
NCT07455851 · Relapsed Refractory Multiple Myeloma (RRMM)
Linvoseltamab, REGN17372+Linvoseltamab
REGN
Regeneron Pharmaceuticals
Phase 1/2Recruiting150Sep 30, 2033Registry ↗
Nov 5, 2026REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
NCT07410117 · Cancer-Associated Thrombosis (CAT)
REGN7508, Placebo
REGN
Regeneron Pharmaceuticals
Phase 3Recruiting1,120Jan 23, 2030Registry ↗
Nov 5, 2026Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral…
NCT07318610 · Peripheral Artery Disease (PAD)
REGN7508, REGN9933
REGN
Regeneron Pharmaceuticals
Phase 3Recruiting7,050Aug 18, 2029Registry ↗
Nov 5, 2026REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthropla…
NCT07213778 · Symptomatic Venous Thromboembolism (VTE)
REGN7508, Acetylsalicylic Acid (ASA)
REGN
Regeneron Pharmaceuticals
Phase 3Recruiting2,000May 17, 2027Registry ↗
Nov 5, 2026Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
NCT07175428 · Atrial Fibrillation (AF)
REGN7508, REGN9933
REGN
Regeneron Pharmaceuticals
Phase 2Recruiting1,200Feb 9, 2027Registry ↗
Nov 5, 2026A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdi…
NCT06541704 · Age-related Macular Degeneration (AMD), Geographic Atrophy…
Pozelimab, Cemdisiran
REGN
Regeneron Pharmaceuticals
Phase 3Recruiting975Jul 31, 2028Registry ↗
Nov 5, 2026A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-…
NCT05744921 · Paroxysmal Nocturnal Hemoglobinuria
Pozelimab, Cemdisiran
REGN
Regeneron Pharmaceuticals
Phase 3Recruiting202Oct 10, 2028Registry ↗
Nov 5, 2026A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Trea…
NCT05137054 · Multiple Myeloma
Linvoseltamab, Daratumumab
REGN
Regeneron Pharmaceuticals
Phase 1Recruiting317Mar 25, 2028Registry ↗
Nov 4, 2026A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma…
NCT07393282 · High Risk Smoldering Multiple Myeloma (HR-SMM)
Linvoseltamab, Daratumumab
REGN
Regeneron Pharmaceuticals
Phase 3Recruiting270Jul 27, 2033Registry ↗
Nov 4, 2026A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea
NCT07235917 · Functional Hypothalamic Amenorrhea, FHA
Mibavademab, Placebo
REGN
Regeneron Pharmaceuticals
Phase 2Recruiting34Jan 28, 2028Registry ↗
Nov 4, 2026A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy Wi…
NCT07222761 · Relapsed and/or Refractory Multiple Myeloma (RRMM)
Linvoseltamab, Carfilzomib
REGN
Regeneron Pharmaceuticals
Phase 3Recruiting915May 21, 2029Registry ↗
Nov 4, 2026A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic…
NCT06836609 · Metabolic Dysfunction-Associated Steatotic Liver Disease, M…
ALN-CIDEB, Placebo
REGN
Regeneron Pharmaceuticals
Phase 1/2Active, not recruiting
was recruiting
118Aug 17, 2027Registry ↗
Nov 4, 2026A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Agains…
NCT06091865 · Diffuse Large B-cell Lymphoma (DLBCL)
Odronextamab, Rituximab
REGN
Regeneron Pharmaceuticals
Phase 3Recruiting904Mar 30, 2028Registry ↗
Nov 4, 2026A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination…
NCT03972657 · Metastatic Castration-Resistant Prostate Cancer (mCRPC), Cl…
REGN5678, Cemiplimab
REGN
Regeneron Pharmaceuticals
Phase 1/2Recruiting345Nov 15, 2027Registry ↗
Nov 3, 2026A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treat…
NCT06465329 · Non Small Cell Lung Cancer, NSCLC
Cemiplimab, Platinum-based chemotherapy
REGN
Regeneron Pharmaceuticals
Phase 2Active, not recruiting184Dec 4, 2029Registry ↗
Nov 3, 2026Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Yea…
NCT02612454 · Atopic Dermatitis
Dupilumab
REGN
Regeneron Pharmaceuticals
Phase 3Completed
was active, not recruiting
880Oct 9, 2026Registry ↗
Oct 30, 2026A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Ce…
NCT07808515 · Locally Advanced Basal Cell Carcinoma
Cemiplimab, Vidutolimod
REGN
Regeneron Pharmaceuticals
Phase 2Not yet recruiting135Nov 13, 2030Registry ↗
Oct 30, 2026An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients Wit…
NCT05363319 · Non-small Cell Lung Cancer
Cemiplimab, Platinum-based chemotherapy
REGN
Regeneron Pharmaceuticals
—Active, not recruiting
was recruiting
509Oct 3, 2028Registry ↗
Oct 28, 2026Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adu…
NCT07901725 · Newly Diagnosed Amyloidosis, Amyloidosis Stage I-IIIA
Linvoseltamab, Daratumumab
REGN
Regeneron Pharmaceuticals
Phase 3Not yet recruiting382Jul 25, 2035Registry ↗
Oct 28, 2026A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and…
NCT05070858 · Generalized Myasthenia Gravis
Pozelimab + Cemdisiran, Cemdisiran
REGN
Regeneron Pharmaceuticals
Phase 3Active, not recruiting288Jul 8, 2025Registry ↗
Oct 27, 2026Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Si…
NCT07753148 · Clonal Cytopenia of Undetermined Significance (CCUS), Low-R…
REGN17235
REGN
Regeneron Pharmaceuticals
Phase 1Recruiting52May 5, 2031Registry ↗
Oct 27, 2026Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Releas…
NCT07609940 · Relapsed/Refractory Multiple Myeloma (RRMM)
Linvoseltamab, Tocilizumab
REGN
Regeneron Pharmaceuticals
Phase 4Recruiting30Oct 11, 2027Registry ↗
Oct 27, 2026Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
NCT07271186 · Diabetic Kidney Disease (DKD)
ALN-ANG3, Evinacumab
REGN
Regeneron Pharmaceuticals
Phase 2Recruiting195Oct 13, 2028Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:20 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances